Nochot Hathai, Loimek Sumat, Priyavoravong Patcharin, Wongkamchai Sirichit, Sarasombath Patsharaporn Techasintana
Department of Parasitology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Office of Disease Prevention and Control Region 12 Songkhla, Department of Disease Control, Ministry of Public Health, Songkhla, Thailand.
Exp Parasitol. 2019 May;200:73-78. doi: 10.1016/j.exppara.2019.03.016. Epub 2019 Apr 4.
The aim of this study was to evaluate the efficacy of oral doxycycline treatment for Brugia malayi as measured by microfilarial and filarial DNA clearance in naturally infected domestic cats.
This study included 8 domestic cats that lived with families that resided in Tak Bai District of Narathiwat Province, which is located in Southern Thailand. The study area is a known B. malayi endemic area. All study cats received doxycycline treatment doses by their respective owners according to a previously described protocol. Briefly, doxycycline (VibraVet) was given orally once a day during weeks 1-4, 10-11, and 16-17. Blood collections were performed at baseline before treatment, and then every month for 12 months after the initial dose of doxycycline to assess microfilaraemia by Giemsa stain, and filarial DNA detection by high-resolution melt (HRM) real-time polymerase chain reaction (PCR).
One month after the start of doxycycline treatment, five of eight cats were negative for microfilaraemia, and 4 of those were negative for filarial DNA. All cats receiving doxycycline treatment were negative for microfilaria by Giemsa stain, and for filarial DNA by HRM real-time PCR within 8 months after receiving the initial dose of doxycycline treatment.
Administration of oral doxycycline to domestic cats naturally infected with B. malayi in disease endemic areas can significantly reduce microfilaraemia at 1 month and filarial DNA was undetectable by 8 months after the initial dose of doxycycline treatment. No recurrence of microfilaraemia or filarial DNA was observed in study cats at 1 year after the start of doxycycline. Included cats appeared to tolerate doxycycline (VibraVet) well, with no adverse drug reactions reported by any study cat owner.
本研究旨在通过检测自然感染马来布鲁线虫的家猫体内微丝蚴和丝虫DNA清除情况,评估口服强力霉素治疗马来布鲁线虫的疗效。
本研究纳入了8只与居住在泰国南部北大年府陶公区家庭共同生活的家猫。研究区域是已知的马来布鲁线虫流行区。所有研究猫均由各自主人按照先前描述的方案给予强力霉素治疗剂量。简而言之,在第1 - 4周、第10 - 11周和第16 - 17周,每天口服一次强力霉素(VibraVet)。在治疗前的基线期进行采血,然后在首次给予强力霉素剂量后的12个月内每月采血一次,通过吉姆萨染色评估微丝蚴血症,并通过高分辨率熔解(HRM)实时聚合酶链反应(PCR)检测丝虫DNA。
强力霉素治疗开始1个月后,8只猫中有5只微丝蚴血症检测为阴性,其中4只丝虫DNA检测为阴性。所有接受强力霉素治疗的猫在首次给予强力霉素治疗剂量后的8个月内,吉姆萨染色检测微丝蚴为阴性,HRM实时PCR检测丝虫DNA为阴性。
在疾病流行地区,对自然感染马来布鲁线虫的家猫口服强力霉素,可在1个月时显著降低微丝蚴血症,首次给予强力霉素治疗剂量后的8个月内检测不到丝虫DNA。在强力霉素开始治疗1年后,研究猫未观察到微丝蚴血症或丝虫DNA复发。纳入研究的猫似乎对强力霉素(VibraVet)耐受性良好,没有任何研究猫主人报告有药物不良反应。